US equities |
MU $928.62 ▼-2.58% NVDA $222.19 ▼-2.77% AAPL $344.31 ▲+0.89% AMD $571.37 ▼-5.64% META $738.97 ▼-3.09% TSLA $366.59 ▼-2.30% SPCX $153.49 ▼-1.95% SNDK $1,418.01 ▼-4.34%
FinancialContent

Alector, Inc. - Common Stock (NQ:ALEC)

1.825 -0.045 (-2.41%)
Delayed Quote Updated: 12:46 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alector, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Alector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s Therapies ↗
Alector (NASDAQ:ALEC) outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer’s disease and two siRNA... 
Via MarketBeat
News headline image
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
From Alector, Inc.
Via GlobeNewswire
Which stocks are most active on Monday? ↗
Via Chartmill
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares... 
Via Benzinga
News headline image
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in the Bank of America CNS Therapeutics Conference
From Alector, Inc.
Via GlobeNewswire
News headline image
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Which stocks have an unusual volume on Friday? ↗
Volume analysis on 2025-10-24: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce ↗
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff. 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Wednesday's pre-market session: top gainers and losers ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Intuitive Surgical Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >